Abstract | OBJECTIVES: METHODS: Men and women who had overactive bladder symptoms were randomized equally to double-blind treatment with 0.05, 0.1, or 0.25 mg of imidafenacin twice daily or a placebo for 12 weeks, and assessed for efficacy and safety. RESULTS: Overall, 401 patients were enrolled and randomized for treatment with 0.1 mg of imidafenacin/day (99 patients), 0.2 mg of imidafenacin/day (100), 0.5 mg of imidafenacin/day (101), or a placebo (101). After 12 weeks of treatment, the number of incontinence episodes was reduced in a dose-dependent manner, and a significant difference between the imidafenacin treatment and the placebo was observed (P < 0.0001). Compared with the placebo, imidafenacin caused significant reductions in urgency incontinence, voiding frequency, and urinary urgency, and a significant increase in the urine volume voided per micturition. Imidafenacin was also well tolerated. The incidence of dry mouth in the imidafenacin groups increased dose-dependently. Even though the percentage of patients receiving 0.5 mg/day who discontinued treatment due to dry mouth was high (8.9%), the percentages in the 0.1 mg/day and 0.2 mg/day groups (1.0% and 0.0%, respectively) were comparable with that in the placebo group (0.0%). CONCLUSIONS: Considering the balance between efficacy and safety, 0.1 mg of imidafenacin twice daily appeared to be a clinically appropriate dose for treating overactive bladder. This dose was therefore selected for further evaluation in large-scale phase III studies.
|
Authors | Yukio Homma, Takuhiro Yamaguchi, Osamu Yamaguchi |
Journal | International journal of urology : official journal of the Japanese Urological Association
(Int J Urol)
Vol. 15
Issue 9
Pg. 809-15
(Sep 2008)
ISSN: 1442-2042 [Electronic] Australia |
PMID | 18637156
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Imidazoles
- Muscarinic Antagonists
- imidafenacin
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Double-Blind Method
- Female
- Humans
- Imidazoles
(administration & dosage)
- Japan
- Male
- Middle Aged
- Muscarinic Antagonists
(administration & dosage)
- Urinary Bladder, Overactive
(drug therapy)
- Young Adult
|